IOVERSOL

Details

Stereochemistry	UNKNOWN
Molecular Formula	C18H24I3N3O9
Molecular Weight	807.1113
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

InChI

InChIKey=AMDBBAQNWSUWGN-UHFFFAOYSA-N

InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf
Curator's Comment: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB09134 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=549d38db-d4ed-4708-8f76-7cdaa157063f

Ioversol is an organoiodine compound that used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is indicated in adults for peripheral and coronary arteriography and left ventriculography, for excretory urography and computed tomography. Injections of contrast media are often associated with sensations of warmth and pain. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Target ID: vessels and anatomical structures Sources: http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?7/48/7950?source=see_link	Activator 1404

Conditions

Condition	Modality	Highest Phase	Product
Cardiovascular diseases 71 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf	Diagnostic	Approved 8307	OPTIRAY 320 Approved Use Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography. Launch Date 5.9944318E11
Urinary system disease 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf	Diagnostic	Approved 8307	OPTIRAY 320 Approved Use Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography. Launch Date 5.9944318E11
Glioma 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019710s052,020923s018lbl.pdf	Diagnostic	Approved 8307	OPTIRAY 320 Approved Use Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography. Launch Date 5.9944318E11

C_max

Value	Dose	Co-administered	Analyte	Population
1.45 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	50 mL single, intravenous dose: 50 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.36 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	150 mL single, intravenous dose: 150 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1.74 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	50 mL single, intravenous dose: 50 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.43 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	150 mL single, intravenous dose: 150 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	50 mL single, intravenous dose: 50 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2793391	150 mL single, intravenous dose: 150 mL route of administration: Intravenous experiment type: SINGLE co-administered:		HYDROGEN IODIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019710s054,020923s019lbl.pdf			IOVERSOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.6 mg/kg 1 times / day single, intravenous (mean) Recommended Dose: 1.6 mg/kg, 1 times / day Route: intravenous Route: single Dose: 1.6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/	unknown, 56 (15-86) n = 1186 Health Status: unknown Age Group: 56 (15-86) Sex: M+F Population Size: 1186 Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/	Other AEs: Angina... Other AEs: Angina Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/

AEs

AE	Significance	Dose	Population
Angina		1.6 mg/kg 1 times / day single, intravenous (mean) Recommended Dose: 1.6 mg/kg, 1 times / day Route: intravenous Route: single Dose: 1.6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/	unknown, 56 (15-86) n = 1186 Health Status: unknown Age Group: 56 (15-86) Sex: M+F Population Size: 1186 Sources: https://pubmed.ncbi.nlm.nih.gov/2687200/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 252

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 252	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020923s026lbl.pdf#page=15 Page: 15.0	no

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY576850	https://www.001chemical.com/chem/87771-40-2
3B Scientific (Wuhan) Corp	3B2-1453	http://www.3bsc.com/index/pro_info.php?id=55169
AA Blocks	AA004LA3	https://www.aablocks.com/goods/Goods/detail?id=AA004LA3
AHH Chemical co.,ltd	MT-52846	http://www.ahhchemical.com/product/MT-52846.html
AK Scientific, Inc. (AKSCI)	71363	http://www.aksci.com/item_detail.php?cat=71363
Achemtek	0104-007219	http://www.achemtek.com/87771-40-2
Alfa Chemistry	AP87771402	https://reagents.alfa-chemistry.com/product/ioversol-cas-87771-40-2-17707.html
Alfa Chemistry	87771-40-2	https://www.alfa-chemistry.com/cas_87771-40-2.htm
Angene	AGN-PC-0BI1NV	http://www.angenechemical.com/productshow/AGN-PC-0BI1NV.html
Aurora Fine Chemicals LLC	A24.076.488	http://online.aurorafinechemicals.com/info?ID=A24.076.488
AvaChem Scientific	3828	http://www.avachem.com/productSearch.asp?3828
BLD Pharm	BD134819	http://www.bldpharm.com/products/87771-40-2.html
BioChemPartner	BCP11109	http://www.biochempartner.com/87771-40-2-BCP11109
BioSynth	Q-201247	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201247.html
Boerchem	BC215938	http://www.boerchem.com/?product_36614.html
CSNpharm	CSN21691	https://www.csnpharm.com/products/ioversol.html
Chem Scene	CS-7483	http://www.chemscene.com/87771-40-2.html
ChemFish Tokyo co.,ltd	3741	http://www.chemfish.co.jp/index.php?id=4618&project=product
ChemMol	30107629	http://www.chemmol.com/chemmol/30107629.html
ChemMol	44005431	http://www.chemmol.com/chemmol/44005431.html
ChemMol	49409497	http://www.chemmol.com/chemmol/49409497.html
Chemspace	CSSB00020618400	https://chem-space.com/CSSB00020618400
Clearsynth	CS-T-56767	https://www.clearsynth.com/en/CST56767.html
Combi-Blocks	QA-1890	http://www.combi-blocks.com/cgi-bin/find.cgi?QA-1890
Finetech	FT-0627284	http://www.finetechnology-ind.com/prod/detail/pub/87771-40-2.html
Hairui	HR132940	http://www.hairuichem.com/en/product/87771-40-2.html
Infinium PharmaChem Pvt Ltd	CatId-124	http://infiniumpharmachem.com/products/ioversol/
Iodochem	ID10099	https://www.iodochem.com/product/87771-40-2
Lab Network	LN01286620	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01286620
MedChem Express	HY-B1410	https://www.medchemexpress.com/Ioversol.html
Molcore	MC576850	https://www.molcore.com/product/87771-40-2
MuseChem	R012692	https://www.musechem.com/product/R012692.html
OChem	6084	http://www.ocheminc.com/index.php?act=psearch&pid=771I402
Parchem	88088	https://www.parchem.com/chemical-supplier-distributor/Ioversol-088088.aspx
THE BioTek	bt-460576	https://www.thebiotek.com/product/others/bt-460576
Yuhao Chemical	RT1905	http://www.chemyuhao.com/87771-40-2.html
iChemical	EBD26632	http://www.ichemical.com/products/87771-40-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.	2001 Dec	11981110
Stabilization of the hydrophilic sphere of non-ionic monomers: are all protected in a similar way?	2001 Dec	11777766
Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT.	2001 Jun	11376257
Renal effects of cardiac angiography with different low-osmolar contrast media.	2001 May-Jul	11499554
Assessing the adequacy of peripherally inserted central catheters for power injection of intravenous contrast agents for CT.	2001 Nov-Dec	11711806
Optimum iodine concentration of contrast material through microcatheters: hydrodynamic analysis of experimental results.	2002 Jul 21	12171337
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].	2002 Nov-Dec	12722628
[Usefulness of CT-perfusion in acute cerebral infarction].	2003 Dec	15001875
Cyclic AMP reverses radiocontrast media-induced apoptosis in LLC-PK1 cells by activating A kinase/PI3 kinase.	2003 Dec	14633127
A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury.	2004 May	15086904
Focal seizure and cerebral contrast retention after cardiac catheterization.	2005 Mar	15730907
CT-guided jejunostomy tube insertion.	2005 Nov	16247172
Comparative study of vascular enhancement on post-contrast CT using three dosages of iodinated contrast media for the aim of detecting brain metastasis in patients with lung cancer.	2006 Feb	16715674
Contrast enhancement in electron beam tomography of the heart: comparison of a monomeric and a dimeric iodinated contrast agent in 59 patients.	2006 Jan	16399037
A simple radiological technique for demonstration of incorrect positioning of a foley catheter with balloon inflated in the urethra of a male spinal cord injury patient.	2006 Jun 20	17619716
Irbesartan attenuates contrast media-induced NRK-52E cells apoptosis.	2006 Oct	16828304
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.	2006 Sep-Oct	16465578
Peritoneography in the diagnosis of peritoneal leaks in peritoneal dialysis.	2007 Apr	17406054
Transplacental passage of non-ionic contrast agents resulting in fetal bowel opacification: a mimic of pneumoperitoneum in the newborn.	2007 Apr	17323055
Modified scan protocol using multislice CT coronary angiography allows high quality acquisitions in obese patients: a case report.	2007 Apr	16821120
NGAL is an early predictive biomarker of contrast-induced nephropathy in children.	2007 Dec	17874137
Fatal anaphylactoid reaction following ioversol administration.	2007 Dec	17557212
[What we can learn from a case of medical malpractice--a case of anaphylactoid shock after administration of nonionic contrast medium].	2007 Jul	17665563
Lymph node enlargement in pulmonary arterial hypertension due to chronic thromboembolism.	2008 Feb	18373821
Comparative rheology of low- and iso-osmolarity contrast agents at different temperatures.	2008 Jan 1	18098191
The fate of infrarenal abdominal aortic aneurysms after stent grafting: influence of thrombosis at side branch ostia.	2008 Jan-Feb	18303295
Direct MR arthrography at 1.5 and 3.0 T: signal dependence on gadolinium and iodine concentrations--phantom study.	2008 Jun	18403628
Multidetector-row computed tomography (CT) of blunt pancreatic injuries: can contrast-enhanced multiphasic CT detect pancreatic duct injuries?	2008 Mar	18332806
A dual contrast injection technique for multidetector computed tomography angiography of Fontan procedures.	2008 Mar	17823851

Patents

Sample Use Guides

In Vivo Use Guide

Optiray (ioversol injection) 240, Optiray 300 or Optiray 320 is recommended for cerebral arteriography. The usual individual injection for visualization of the carotid or vertebral arteries is 2 to 12 mL. Aortic arch injection for a simultaneous four vessel study requires 20 to 50 mL. Total procedural doses should not usually exceed 200 mL. Optiray 300, Optiray 320 or Optiray 350 is recommended for peripheral arteriography. The dosage is 20-60 ml. Optiray 320 or Optiray 350 is recommended for coronary arteriography. The dosage is 6-40 mL. Optiray 320 is recommended for visceral arteriography, renal arteriography, and aortography procedures. The dosage is 9-45 mL. Optiray 240, Optiray 300, Optiray 320 or Optiray 350 is recommended for venography. The usual dose is 50 to 100 mL per extremity with smaller or larger volumes indicated in some cases. Dosage should not usually exceed 250 mL.

Route of Administration: Intravascular

In Vitro Use Guide

Ioversol 320 mgI/mL did not significantly inhibit clot lysis (14.9+/-11.5% decrease vs. control; p>0.3).

Name

Type

Language

IOVERSOL

Official Name

English

IOVERSOL [JAN]

Common Name

English

N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-(N-(2-HYDROXYETHYL)GLYCOLAMIDO)-2,4,6-TRIIODOISOPHTHALAMIDE

Systematic Name

English

MP 328

Code

English

OPTIRAY

Brand Name

English

IOVERSOL [VANDF]

Common Name

English

IOVERSOL [MI]

Common Name

English

IOVERSOL [MART.]

Common Name

English

IOVERSOL [ORANGE BOOK]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)(2-HYDROXYETHYL)AMINO)-2,4,6-TRIIODO-

Systematic Name

English

IOVERSOL [USAN]

Common Name

English

Ioversol [WHO-DD]

Common Name

English

MP-328

Code

English

IOVERSOL [USP-RS]

Common Name

English

ioversol [INN]

Common Name

English

IOVERSOL [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QV08AB07